PSMC6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1478606	0.58	12/20
SCHEMBL607010	0.56	12/20
SCHEMBL608381	0.53	12/20
SCHEMBL3170187	0.51	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL1477637	0.57	11/20
SCHEMBL607972	0.55	11/20
SCHEMBL608782	0.54	11/20
SCHEMBL609278	0.54	11/20
SCHEMBL607553	0.54	11/20
SCHEMBL605822	0.54	11/20
SCHEMBL606932	0.53	11/20
SCHEMBL1477893	0.53	11/20
SCHEMBL608362	0.53	11/20
SCHEMBL608599	0.53	11/20
SCHEMBL1327441	0.53	11/20
SCHEMBL605129	0.52	11/20
SCHEMBL3170843	0.52	11/20
SCHEMBL608009	0.52	11/20
SCHEMBL1478157	0.52	11/20

Clinical trials — most relevant to PSMC6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib	PHASE3	COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis	PHASE2	RECRUITING
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma	PHASE2	WITHDRAWN
Bortezomib in Treating Patients With Mantle Cell Lymphoma	PHASE2	COMPLETED
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	PHASE2	COMPLETED
Treatment of Adult-Onset Immunodeficiency With Bortezomib	PHASE2	UNKNOWN
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma	PHASE2	WITHDRAWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2	PHASE1	COMPLETED
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy	nan	COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMC6 binder may also engage these)

Protein	Name	Similarity
Q2KIW6	—	1.000	Q2KIW6 →
P62334	—	1.000	P62334 →
P62335	—	1.000	P62335 →
P54778	—	1.000	P54778 →
Q8SQK0	—	1.000	Q8SQK0 →
Q25544	—	1.000	Q25544 →
Q01939	—	1.000	Q01939 →
Q9MAK9	—	1.000	Q9MAK9 →
Q54PN7	—	1.000	Q54PN7 →
Q8SR13	—	1.000	Q8SR13 →
Q5E9F9	—	0.999	Q5E9F9 →
P46472	—	0.999	P46472 →
Q5R8D7	—	0.999	Q5R8D7 →
Q54PJ1	—	0.999	Q54PJ1 →
Q9SEI4	—	0.999	Q9SEI4 →
A3CV35	—	0.999	A3CV35 →
Q63347	—	0.999	Q63347 →
P46471	—	0.999	P46471 →
Q8PY58	—	0.998	Q8PY58 →
Q4R4R0	—	0.998	Q4R4R0 →
PSMC2	26S proteasome regulatory subunit 7	0.998	landscape →
Q8TI88	—	0.998	Q8TI88 →
P62196	—	0.998	P62196 →
O42586	—	0.998	O42586 →
Q2FQ56	—	0.998	Q2FQ56 →
Q9SEI3	—	0.997	Q9SEI3 →
O17071	—	0.997	O17071 →
P78578	—	0.997	P78578 →
Q8SRH0	—	0.996	Q8SRH0 →
Q4R7L3	—	0.996	Q4R7L3 →